<SEC-DOCUMENT>0001558370-24-000672.txt : 20240131
<SEC-HEADER>0001558370-24-000672.hdr.sgml : 20240131
<ACCEPTANCE-DATETIME>20240131170750
ACCESSION NUMBER:		0001558370-24-000672
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240131
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240131
DATE AS OF CHANGE:		20240131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		24583862

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adap-20240131x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adap="http://www.adaptimmune.com/20240131" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityCentralIndexKey" id="Tc_NqR6uEbXWkCHjR5Giegozw_2_1">0001621227</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:AmendmentFlag" id="Tc_mL90aPEUykWvoCyueaLVgw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityTaxIdentificationNumber" id="Hidden_-sH3hZWHxUacgZC59ij7Ow">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adap-20240131.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7496f995_a2ab_489f_8c05_ca9df3b19c92"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES </b><b style="font-size:18pt;font-weight:bold;"><br/></b><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:DocumentType" id="Narr_LJqa6Rl9hE2XNzLV7fb-vQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported):<b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_ysdCSWw3eUaQzyQT4U9xPg"><b style="font-weight:bold;">January 31, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityRegistrantName" id="Narr_xFvbOgvva0yToyAQhT9shQ"><b style="font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a955ef0e_e52b_4858_9ce4_6782eccbb535"></a><a id="Tc_xRAyH0pfsUCeAny5hEyn7w_2_0"></a><a id="Tc_noiW6mF2a0WaaeqwMcfLsg_2_2"></a><a id="Tc_f-y7QLzrGEmL_XiNFEb_MA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_MORhMAF0qUaf6RoSbOfa_w_1_0"><b style="font-weight:bold;">England and Wales</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityFileNumber" id="Tc_r4_Uqx3VaUmYNd-ufN7yyQ_1_2"><b style="font-weight:bold;">1-37368</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-sH3hZWHxUacgZC59ij7Ow;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Not Applicable</b></span></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br/>incorporation)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityAddressAddressLine1" id="Narr_WjdoilNGNke9TE9uMiwa6A"><b style="font-weight:bold;">60 Jubilee Avenue</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityAddressAddressLine2" id="Narr_W7iUeD2FoUuopaUkju-gcQ"><b style="font-weight:bold;">Milton Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityAddressCityOrTown" id="Narr_QF3-ZaciE0KZIP59e18lvw"><b style="font-weight:bold;">Abingdon, Oxfordshire</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:EntityAddressPostalZipCode" id="Narr_Jp7TbG1HW0qPEkR58EUlLg"><b style="font-weight:bold;">OX14 4RX</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_8EyJspNXIkiAEnlVuioz_w"><b style="font-weight:bold;">United Kingdom</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:CityAreaCode" id="Narr_rY0D0vKLvkKs1acbV_Ae3Q"><b style="font-weight:bold;">44</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:LocalPhoneNumber" id="Narr_xUiUCGUtM0C8n95C_l8FRg"><b style="font-weight:bold;">1235 430000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_na9Xyrh6Uk6opbGVegWwHg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_LOIkMJK1y02NztR3l1o_NA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_T7mD00MeQEGzDjXj_PXolQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_GpSCgi-UNke-j14QFhvk_Q"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_602dac61_edc2_4936_8590_9ecf753fb00c"></a><a id="Tc_nUZ0O-goQkOB4gWtAQr9_g_0_0"></a><a id="Tc_O-EfydggnUaNpTnuCZr6BA_0_2"></a><a id="Tc_7HMgN6m0NUCK-AgtXWxDhw_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">registered</b></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:Security12bTitle" id="Tc_5nmTpGcXVkWgvvMK_nQJTQ_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" name="dei:TradingSymbol" id="Tc_WSNc935yjEKIBEXLdF7vmQ_1_2">ADAP</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_QenH9gwsSkqffKO9RQcUCw_1_4">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_5K4_y5ctTkuDB4V9junSsQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_067fba00_e8e9_4345_b46d_0fe0fabbbdb3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.01</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Other Events. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 31, 2024, Adaptimmune Therapeutics plc (the &#8220;Company&#8221;) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company&#8217;s Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d)&#160; Exhibits.</p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="adap-20240131xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated January 31, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAPTIMMUNE THERAPEUTICS PLC</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 31, 2024</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adap-20240131xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 1/31/2024 09:53:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#4a4a4a;background:#e6e6e6;"><img src="adap-20240131xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:24pt;width:150pt;"></font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:center;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade  </i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PHILADELPHIA and OXFORD, UK, January, 31, 2024</b><font style="font-size:12pt;"> &#8211; Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August, 4, 2024.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Adrian Rawcliffe, Adaptimmune&#39;s Chief Executive Officer:</b><font style="font-size:12pt;"> &#8220;</font><font style="font-size:12pt;background:#ffffff;">The FDA&#8217;s acceptance of the BLA submission brings us one step closer to redefining treatment for people with </font><font style="font-size:12pt;">synovial sarcoma. Our</font><font style="color:#222222;font-size:12pt;"> franchise has great potential and, if approved, we have the capabilities and the capital to launch afami-cel - the first engineered T-cell therapy on the market for a solid tumor cancer.</font><font style="font-size:12pt;background:#ffffff;">&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Dennis Williams, PharmD, Senior VP of Late-Stage Development: </b><font style="font-size:12pt;white-space:pre-wrap;">&#8220;Historic outcomes are poor for advanced synovial sarcoma, with low objective response rates for second-line therapies and overall survival of less than 12 months for people who have received two or more prior lines of therapy.  In clinical trials, afami-cel has demonstrated an impressive response rate of ~39% among heavily pre-treated patients with advanced synovial sarcoma and about a 17-month median survival. This regulatory milestone is a testament to our teams&#8217; relentless work to deliver a novel treatment option to more people diagnosed with synovial sarcoma.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;">This acceptance is supported by positive data from Cohort 1 of the pivotal trial SPEARHEAD-1, which met its primary endpoint for efficacy. Data from the trial were presented at the </font><u style="color:#1155cc;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">Connective Tissue Oncology Society (CTOS) 2023</u><font style="font-size:12pt;"> Annual Meeting. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Afami-cel</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">Afami-cel is an engineered T-cell receptor (TCR) T-cell therapy, targeted to the MAGE A4 cancer target, and designed as a single-dose treatment for advanced synovial sarcoma. The last FDA approved therapy for treatment in this setting was for Votrient in 2012. The BLA submission for afami-cel was supported by clinical data from the SPEARHEAD-1 pivotal trial, which has met its primary endpoint for efficacy. ~39% of patients who received afami-cel had clinical responses with a median duration of response of ~12 months (</font><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">CTOS 2022</u><font style="font-size:12pt;">). Median overall survival (mOS) was ~17 months in SPEARHEAD-1 compared to historical mOS of &lt;12 months for people with synovial sarcoma who received two or more prior lines of therapy.</font><sup style="font-size:9pt;vertical-align:top;">1</sup><font style="font-size:12pt;"> Seventy percent of people with advanced synovial sarcoma who respond to afami-cel are alive two years post-treatment.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About synovial sarcoma</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">There are more than 50 different types of soft tissue sarcomas which are categorised by tumors that appear in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.</font><sup style="font-size:9pt;vertical-align:top;">1</sup><font style="font-size:12pt;"> Synovial sarcoma accounts for approximately 5% to 10% of all soft tissue sarcomas (there are approximately 13,400 new soft tissue cases in the U.S. each year).</font><sup style="font-size:9pt;vertical-align:top;">2</sup><font style="font-size:12pt;"> One third of patients with synovial sarcoma will be diagnosed under the age of 30.</font><sup style="font-size:9pt;vertical-align:top;">2</sup><font style="font-size:12pt;"> The five-year survival rate for people with metastatic disease is just 20% and most people undergoing standard of care treatment for advanced disease experience recurrence and go through multiple lines of therapy, often exhausting all options.</font><sup style="font-size:9pt;vertical-align:top;">3</sup></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;vertical-align:top;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><sup style="font-size:9pt;vertical-align:top;">1.</sup><font style="font-size:12pt;"> </font><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html</u><font style="font-size:12pt;"> </font><sup style="font-size:9pt;vertical-align:top;">2.</sup><font style="font-size:12pt;"> </font><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">Synovial Sarcoma - NCI (cancer.gov)</u><font style="font-size:12pt;"> </font><sup style="font-size:9pt;vertical-align:top;">3.</sup><font style="font-size:12pt;"> Aytekin MN, et al. </font><i style="font-size:12pt;font-style:italic;">J Orthop Surg (Hong Kong)</i><font style="font-size:12pt;">. 2020;28(2)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Adaptimmune</b><b style="font-size:12pt;font-weight:bold;"><br></b><font style="font-size:12pt;">Adaptimmune is a cell therapy company out to redefine cancer treatment. With personalized medicines that radically improve the patient&#8217;s experience with the therapy as much as the therapy itself, Adaptimmune is tackling difficult-to-treat solid tumor cancers so that patients and families may experience more unforgettable and important personal moments. The Company&#39;s unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;"> </b><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward-Looking Statements</b><b style="font-size:12pt;font-weight:bold;"><br></b><font style="font-size:12pt;">This release contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2022, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;"> </b><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Adaptimmune Contacts</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Investor Relations</b><b style="font-size:12pt;font-weight:bold;"><br></b><font style="font-size:12pt;">Juli P. Miller, Ph.D., VP, Corporate Affairs and Investor Relations</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">T: +1 215 825 9310</font><font style="font-size:12pt;"><br></font><font style="color:#0563c1;font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">M: +1 215 460 8920</font><font style="font-size:12pt;"><br></font><u style="color:#1155cc;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">Juli.Miller@adaptimmune.com</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#0563c1;font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Media Relations</b><b style="font-size:12pt;font-weight:bold;"><br></b><font style="font-size:12pt;">Dana Lynch, Senior Director of Corporate Communications</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">M: +1 267 990 1217</font><font style="font-size:12pt;"><br></font><u style="color:#1155cc;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">Dana.Lynch@adaptimmune.com</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#0563c1;font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#ffffff;font-size:12pt;"><img src="adap-20240131xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:24pt;width:150pt;"></font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>adap-20240131xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adap-20240131xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  @ ,@# 2(  A$! Q$!_\0
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MHVS1O$>F+NEMHO[_ )O\4?\ ]AO2OG<1*4ZTI(_2,LJ8:OA;SC[T8\LOYO\
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COA=X1\)7SWFB>&M)TJ\?_EO:6:1,?^!***M8AI:,CV9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>adap-20240131xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adap-20240131xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  @ ,@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[2^.'[0>B
M?#_78?!VKP:W86M_:_O=>T]=GV;=T\KY?G;_ '?NUXWH/C#Q!^S!XETJYGUR
M7QE\*_$$N^#4=WF^5N_C_P!F7_8_C_WON]6EG\2+CQW<>"/B3HS^,O!6O.^W
M4+&R:6+3G;?L99=GR[?]K[M<MX*^%/BB#P9\4_ACK.BZI<Z59K+?Z!?36C>5
M+/$WR>4W_37Y/D7_ &_[U>M35.,>61PRE+F/H7XS_&[1O@_\,9?$\KK=O.JI
MI]M$W_'U*_W-O^S_ !?[JU\F^&];U30M2LOC3\7?%VI:=/>-OTCPWIC;9;R+
M^YY7\,7W/_'-[UF6'@GQO\5/$7PC\&>(?"VM6^@Z"&^V7%]IT\43+YKML=F7
M_GE$B_\  ZZX^ =9^(7QY\:>,O&WA35KSPUX5@=-'T>:QE"7_E;UB6)-O[W?
MM9O^!I7B8B,HU)11^B973H8?#>_+WI1YI?S?X8^I]1? WXOVOQG\'0Z[:Z9=
MZ/\ O&B:WNU_\>5OXEKTR3I_]:OE[]FC4/C'XL\57OB?QG&NB^%)8I;>V\/S
M0?9YHFWIL=5V;O[Z_.]>W_%CQQ#\./ NJ^(9$\V:UB_<0?\ /6=OEB3_ +Z8
M55+FD?+8ZC&E6E&'^9O:9K^G:O=7MK8ZA;WEQ92^5<Q6\JN\#?W'7^&M<C-?
M+/@SPM??L^>+?!NLZG<R31>+U_L_Q)*[?*NJ2LTL4O\ WV[Q5[#\3?BHG@%M
M*TVRTV?Q#XDU:5HM/TFW?8TNW[[N[?=5?[]=$J?O<M,\^,CM-<UJR\-Z3=ZG
MJ=REII]K&TL]Q+]U%J6PU"#4[."[MI%FMYXUEC=?XE:OF_XU_$/QG8_"GQ+9
M>,_",.FVM]8O;P:GI5]]JBCE;[JRILW+_OUZ!#XD\8:7X-\)VWA7PK#KIETJ
MW\V[N]12UBM_W2?>^7<W_ *)49<O,'M#V"F5Y%X9^,6KR>*IO"OB[PT?#VM/
M9O>6+6]XMU;WJ+]_8^WY&_V6KF?!OQX\6_%?P[::GX.\$0S?+F\N-2U#RK>*
M7_GC%\FZ5MO\7R*NZH]C(7M(GT'3$=7^96W+7AJ?&;6/$WAOQ;I!\,?V=XXT
MF#%SH-W=JB/$W_+6*7;\R[:R/V6]:\7R?#?PE8R>&[2/PU]FDVZM_:>^5OO_
M /+OL_O?[=7[&7+S$^T/?=,U6TUBRBO+&YAN[67[DMN^]6_X%6E7R_X6_:%M
M=(\)_#5=#\$K;6_BK^T5MM(TR?\ X]Y8)=J(OR;?G9_F?Y=E=!K?Q^\2_#O5
M+5/'?@K[!I^H[DL;K1+S[;NG_@@9=B?,U'L9![2)] 45X%K7QN\9^!OL6J>,
M/!$&E>%[JX6">[M-3\^XL-_RJ\J;/_0*OZ]\:]7A^(VL>!]!\+/K6JVMM!<P
M3/>>5;[77YVE?9\BI\G][=OH]E(?M(GM=+D5\^K^T%XCTOQ)+X2UGP3*GCB1
M5ETRQL;Q7M+^+Y_WOFLO[I4V-NK9T+XP>(],\=:5X5\;^%[?0KC65E_LS4+*
M\^T6\[(NYXF^1=KU#HRB'M(GM/%-Q7"?";XB-\2O#EWJC6/V!H-0N++RO-\W
M=Y3[-U<MXJ^/$OAR\^)5JNBK<_\ "&VEG=*SW.S[5YZ;_P"[\NVCV<I2Y2N:
M)[+17@X^+?C[4=$C\2Z%\/EO=",'VA4N-1\J]NHMFYFBBV?]\[OF?Y:UK_\
M: TV;P7X;U?0=-N=:U/Q0SII.CPLJ2RRK_K=S?P*G\;_ ,-'L9![2)[%17B_
M_"W/$_A#6=*M_'?A6STO2]4G2U@U;2K_ .T103O]Q)59%V_[]%'L:@>TB>8)
M>?$BW\=W'C?XDZR_@WP5H+OMT^QO&BBU%UW[%6+?\V[_ &OO5R_@WXK^*)O!
M?Q4^)VLZUJ5MI-XLMEH%C->/Y44\K?)Y2_\ 3+Y/G3_;_NU[#\;_ -GW1/B#
MKJ>+M6EUJ^@TZU_>:#8-O^T[>GE#JK_[GWOEKQ[P]X/\0?M.^(]*M9]%E\(?
M"OP_+L@T[8\7F[?X?]J7_;_@_P![[WJ4W3E'FD<DN;F//K#QMXW^%?B+X2>,
M_$/BK6KG0=>#?;+>^U&>6)5\UUWNK-_SRE5O^ 5UI\?:S\.OCSXT\&^-O%>K
M6GAKQ9 [Z/K$M]*Z6'F[VB:)]_[K9N9?^ )7TQ\:/@CHWQ=^&MQX8E1+-XE5
MM.N8E_X]I4^Y_P !_A_W6KY/\-Z'JFNZE9?!;XN^$=2U&XMFV:1XCTQ=TMK%
M_?\ -_BB_P#L-Z5XE:4IU)21^B994PU?#>_'WHQY9?S?XH^A[+^S/8?&'POX
MIO?#/C*5==\*Q12W%MX@FG\^65]Z;$5MV[^\WSUM?%VVUKXN?%>P\'^'-0MK
M&+PJL6M:A=7$'GQ?:F;_ $>%D_W=[UWWP.^#]M\%_!B:%;:G=ZQ\S2M<7;?^
M.HO\*UVMEHFG:5=7<]I96UM/>OYMS-%&J/._]YO[U:T9>S]X^4QU2->M*4/A
M_P# 3Q#Q_P#!KXG>/O#%[HVJ^/-'N;67:VQ-%\I]RON7YM_RUQ'A_P")N/&O
MP_\ '_BG_1K>'3[KPSJ]Q+]W3M11_G:7^YOKZ^ %8/\ PB6@^1J<#Z-8)%J3
MM+?)]F3;=-_>E_O?\"KIC7]WEE$\[V9XY^TK\4_#K_"/7]*L]0L]:U+4;-T@
ML[&597V_Q2MLW;43[VZN<T34Y?%?CFP\)Z[XJU#PQI%CX>TZXTZTL;S[&^IN
M\7[U_-^^VS[NRO==+^%_A#0K6]M-/\*Z396UZNRYB@L8E6=?[K_WJL:_\/?#
M'BFSM[35]!TW4;6U^6&*ZM4=8O\ <_NTXUHQCRA[.1\YW%MHFF_M#>"M/T;Q
M%JGB#[/8ZIY_V[46OXH&\C[JNWW6_O)_N5O?LH?%#P[#\(]$T2]N[?1-3L$E
M=K>^D\@21-*[>;%N^\O/_?5>U1^!="M+.W&GZ-86<ME%,MFT5JB?9O-7Y]G'
MR[OXJXOX;_ W3=*^%6@>&O&&CZ3KU[ID4J[G@^T1+NE=_D9UW?Q54JT91Y9$
M>SE&1R&CZA!\3OCKXD\2^'V^W:+IGAEM#EU"W^>*ZNFE\W9$_P#%LK:_9;\7
MZ+<_!CPIIL>K64FJQ021/8^>OVC>KON79]ZO8-(T:QT&QBLM-L8-/LHOECM[
M2)8HD_X"M9-A\.?#&E:]+KEIX?TVVUB7<S7L5HB7#;OO?/67MHRCRE^S/EGX
M&#]]^S5_N^(__9J]F_:?3]Q\,?E_YGG2_P#VK7H]EX-T#37T_P"R:'86SZ7Y
MOV'R;9$^R^;_ *WRL+\F_P#BVU<U;1+'5_L_]HV-M=_99TNH/M$2R^5*OW)4
MW?==?[U$JO-4YAQC[IYA^US_ ,FZ^+?]VV_]*(JI_#J/?^TG\0_^P/I?_H+U
M[!K.C6/B"P>QU*Q@U&RE&)+>[B26)O\ >5JBM=#T^RU&XU".RMX;^X54ENTA
M59957[JL_P#%4QJ<M/E%R^\>6>)(U_X:L\'_ /8O7G_HU*3X\?\ )0OA'_V'
M7_\ 15>K/H>GMJT6IR6-L]_%$T4=T\2^:B?W=W]VB^T/3M5GM9[RQM[BXLI/
M-MI9XE=X&_OJ?X:7M-8AR'A'[._C71O"VD^*O"^LZE::/K6EZY>M+;WTZP-Y
M3/O65=W\/SUYUXI\3V/B]OVC-5TP^;I\NG:6L-P/^6JJCKO3_9^6OJ7Q#\,_
M"?BB_2^UGPWI.JWJ+M6>[LTE<#_>:K+>"]!NDU#S='L'6_C2*[5K9/WZK]U9
M?[VVME6C&7M.4GV<B;P8G_%&Z%\O_+A!_P"BEKXL\#:<VD>&/A+XGO-9O_#^
M@(VJ:;/JNG[/] E:ZEV;]R.JH_W*^Z(88[6%(HE6*)%V*B?=6LJW\+:/8Z*V
MD6VE6-MI3*RFQAME2#YOO?)]W^]44\1[/F*E3YCPGQQX2\*^(--LM#U[XPZU
MJEOJT\44%C#/92O/+O\ DV>5;[OO?Q45[+X>^%WA'PI?M>:)X:TG2;I_^6MI
..9I$__?2T5:Q$B/9G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>adap-20240131.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/31/2024 9:54:03 PM-->
<!--Modified on: 1/31/2024 9:54:03 PM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2023" targetNamespace="http://www.adaptimmune.com/20240131" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:adap="http://www.adaptimmune.com/20240131" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20240131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20240131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="adap_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>adap-20240131_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/31/2024 9:54:03 PM-->
<!--Modified on: 1/31/2024 9:54:03 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="adap-20240131.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="adap_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adap_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>adap-20240131_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/31/2024 9:54:03 PM-->
<!--Modified on: 1/31/2024 9:54:03 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adap-20240131.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adap-20240131.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638423348433018631" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638423348433018631" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638423348433018631" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638423348433018631" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638423348433018631" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638423348433018631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638423348433018631" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638423348433028563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638423348433028563" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638423348433028563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638423348433028563" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638423348433029859" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638423348433029859" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry_638423348433029859" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638423348433029859" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638423348433029859" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638423348433029859" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638423348433029859" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638423348433029859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638423348433029859" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638423348433038412" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638423348433038412" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638423348433038412" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638423348433038412" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638423348433038412" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638423348433038412" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638423348433038412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638423348433038412" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140121522991120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adap_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adap_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adap_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MW:G7MA5_J5,:LH$#):V9>F'.\-=?O*[[$2%OE^1M3+TBG[^FK X.G]X[_89
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( /B(/UB7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ^(@_6!PX9>H_ 0
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M 5!+ 0(4 Q0    ( /B(/U@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ^(@_6/JKN9;O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ ^(@_6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #XB#]8&$]@290$  "6$0  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ ^(@_6)^@&_"Q @  X@P   T              ( !V P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #XB#]8EXJ[',     3 @  "P
M@ &T#P  7W)E;',O+G)E;'-02P$"% ,4    " #XB#]8'#AEZC\!   \ @
M#P              @ &=$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M^(@_6"0>FZ*M    ^ $  !H              ( !"1(  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^(@_6&60>9(9 0  SP,  !,
M             ( ![A(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  .!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adap-20240131x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adap-20240131.xsd</File>
    <File>adap-20240131_lab.xml</File>
    <File>adap-20240131_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="adap-20240131x8k.htm">adap-20240131x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adap-20240131x8k.htm": {
   "nsprefix": "adap",
   "nsuri": "http://www.adaptimmune.com/20240131",
   "dts": {
    "schema": {
     "local": [
      "adap-20240131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20240131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20240131_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "adap-20240131x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adap-20240131x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adap-20240131x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "adap_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptimmune.com/20240131",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-24-000672-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-000672-xbrl.zip
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MQ(4!W[%-]7OBO3>^HFKK(?P8^"-S]_]02P,$%     @ ^(@_6%FVCLAH$
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M_1]02P$"% ,4    " #XB#]8R2U)K,P#   ^#0  $0              @ $
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J+3(P,C0P,3,Q>&5X.3ED,2YH=&U02P4&      4 !0!- 0  [C$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>adap-20240131x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20240131.xsd" xlink:type="simple"/>
    <context id="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_NqR6uEbXWkCHjR5Giegozw_2_1">0001621227</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_mL90aPEUykWvoCyueaLVgw_3_1">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Hidden_-sH3hZWHxUacgZC59ij7Ow">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_LJqa6Rl9hE2XNzLV7fb-vQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_ysdCSWw3eUaQzyQT4U9xPg">2024-01-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_xFvbOgvva0yToyAQhT9shQ">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_MORhMAF0qUaf6RoSbOfa_w_1_0">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_r4_Uqx3VaUmYNd-ufN7yyQ_1_2">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_WjdoilNGNke9TE9uMiwa6A">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_W7iUeD2FoUuopaUkju-gcQ">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_QF3-ZaciE0KZIP59e18lvw">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_Jp7TbG1HW0qPEkR58EUlLg">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_8EyJspNXIkiAEnlVuioz_w">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_rY0D0vKLvkKs1acbV_Ae3Q">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_xUiUCGUtM0C8n95C_l8FRg">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_na9Xyrh6Uk6opbGVegWwHg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_LOIkMJK1y02NztR3l1o_NA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_T7mD00MeQEGzDjXj_PXolQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_GpSCgi-UNke-j14QFhvk_Q">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_5nmTpGcXVkWgvvMK_nQJTQ_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_WSNc935yjEKIBEXLdF7vmQ_1_2">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Tc_QenH9gwsSkqffKO9RQcUCw_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_31_2024_To_1_31_2024_DXgij3t2vka1TZ-2Z6lC_Q"
      id="Narr_5K4_y5ctTkuDB4V9junSsQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
